Search company, investor...

Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
dynamk.vc

Investments

21

Portfolio Exits

2

Funds

2

About Dynamk Capital

Dynamk Capital is a venture capital firm investing in early stage life sciences companies. Dynamk's investment strategy is centered on identifying companies developing technologies, tools and services that enable the full biopharma continuum across discovery, development and manufacturing of therapeutics.

Headquarters Location

473 Sylvan Avenue

Englewood Cliffs, New Jersey, 07632,

United States

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest Dynamk Capital News

Meeting on the Mesa: Biotech Investing Deal Makers and Breakers

Oct 11, 2023

At the Cell & Gene Meeting on the Mesa 2023, a panel of financial stalwarts offer companies advice for when to go public and how to manage a company for long-term success October 11, 2023 By Jonathan D. Grinstein, PhD Carlsbad, CA—Across the board, biotech investing in 2023 has seen a retraction from the high levels seen the past three years: venture investment has dropped and companies large and small have lost value. However, that doesn’t mean that biotech investors have lost interest or abandoned ship. In fact, with the FDA reviewing submissions for three cell and gene therapies in Q4, investors are looking beyond the discovery and development phase and into the manufacturing and commercialization of these potentially revolutionary medicines—a theme that has taken hold at the 2023 Cell and Gene Meeting on the Mesa. To get there, cell and gene therapy companies will have to do more than fly by on the seat of their pants, hoping to just live another day. Instead, there’s a sentiment amongst investors that now is the time to show a vision for the long run if biotech hopes to have financial support to carry them through until the headwinds die down and into the tailwinds for smooth sailing. Is this the new normal? According to Dynamk Capital’s market analysis, the size and count of deals—mergers and acquisitions (M&A) and initial public offerings (IPOs)—have dropped from the 2020 to 2022 levels through the pandemic. But with three quarters complete in 2023, their analysis shows that the industry numbers are on par with 2018 and 2019 levels, perhaps even higher. Beyond some outliers such as Danaher’s acquisitions of Aldevron and Cytiva as well as the Thermo-PPD deal, Daniella Kranjac, founding partner and managing director at Dynamk Capital, said the trend for deals is pretty healthy. While recent transactions aren’t pulling in deals of 20x revenue as seen during the pandemic, they’re also not at the 3–6x revenue multiples seen in 2018–2019. The industry is at the “new normal,” she said, which is in the 10–15x range. Valerie Dixon, managing director at Morgan Stanley, says it is less a “new normal”, and more of a reversion to the historical mean. It is foolish to hope for the same “irrational exuberance” of the market to return to pandemic levels and that things won’t change back to how they were in 2020 and 2021, she said. “They’re not going to be saved by a white knight and get 15x as much revenue for their company. That’s not happening!” Kicking the can down the road While some investors, board members, and founders have been trying to stay afloat in the turbulent economic climate, Dixon said the perception that they can just kick the can down the road and stretch their cash for another two to four quarters is irrational, even in the context of recent geopolitical events—Russia and Ukraine and now Israel and Palestine. “You can’t manage your balance sheet anticipating World War III,” said Dixon. “You need to be managing your own business for a two to three-year timeframe, not for next quarter or making that month’s quota.” Instead, Dixon believes that managing a biotech business today requires creating long-term, enduring, profitable growth. That’s what funders think is most credible. “When you can tell a story about how you’re investing for long-term growth, then [the investors] will be there for your expansion capital or your growth capital when you need it,” said Dixon. “If they take that long-term mindset with you, that means that you can have confidence that they’re going to have capital that’s going to grow with you along the way. It’s not growth at any cost; it’s making sure you’re doing responsible growth and you’re hitting… milestones that will get you to that next inflection point.” While Sean Mackay, Operating Partner at Casdin Capital, is excited about the numerous companies with great products in great markets, he won’t invest in a company if they can’t support their own operating expenses. For Mackay, it comes down to the return on investment from capital. Consistency is key, Mackay insisted. He wants to know that a prospect’s revenue isn’t random and that a particular move is devoted to a big market that the company is creating or disrupting, which is harder to do. A company’s capital-raising process has to increase the number of shots on goal and, thus, increase the probability of raising the money. To succeed, Mackay says companies need to be creative and expand their funnel instead of just hopping to the next shiny thing. To IPO or not IPO Although there have been signs of life for investing in healthcare and biotech—nine deals so far in 2023 (eight in biotech)—today, only three are trading around issue price. Some 2021 biotech IPOs, Dixon notes, are trading as low as 85% below the original issue price. “Just because you’re going public doesn’t mean everything’s great,” said Dixon, who has led Morgan Stanley’s efforts in life sciences tools and diagnostics. “You still have to pay attention to aftermarket performance… and not just be the first one out of the gate. Be consistent in execution and a good steward of the capital that you raise. Maybe they [went] public too early, took their eye off the ball, or any number of factors—all those things play into the success of an IPO.” Kranjac’s guidance to founders trying to get term sheets done in this market environment and the near future is to make sure they are thinking about who they bring to the table— board members and investors who understand the market and can be helpful in terms of forging additional relationships, whether for investments, operations, or talent. There is no magic wand to secure a deal sheet for financing, but Kranjac shared the advice she can give the founder of an early-stage company: although they may have the luxury of being pre-revenue and not having reportables on a monthly or quarterly basis, they should be raising as much money as possible. “In this environment, the guidance that we’re giving our portfolio companies, and even companies that we’re looking at going forward, is don’t wait,” said Kranjac. “There were a number of folks that early in the year said, ‘We’re going to wait until the fall when the market’s better or until [JP Morgan] 2024, when things are going to be great. Don’t wait!” As to how to value a company, Mackay said that during the 2019 and 2022 period, research analysts might have understood the liquidation value for a sale. But when there’s no M&A activity, that number is more difficult to calculate. The huge push by big pharma to invest in new therapeutic modalities like cell and gene therapies is evidence, according to Mackay, that the industry’s “tailwinds” appear to be very strong. Dead cells don’t cure cancer A major early theme of the 2023 Meeting on the Mesa has been manufacturing and commercialization. Along these lines, while the panelists are all excited about the development of cell gene therapies and the enabling tools that go along with them, they’re keeping a close eye on companies involved in manufacturing and commercialization. Kranjac agreed that bioproduction is exciting because there are going to be many such medicines. And those are exactly the types of companies, like RoosterBio, Curi Bio, and CellFE, that Dynamk has been adding to its portfolio. “You can’t take your eyes off the ball on the manufacturing process and the tools that help with potency, stability, purity, and quality control—dead cells don’t cure cancer,” said Dixon. “When there are huge acquisitions with outsourced manufacturing and you start seeing the Thermo Fishers and Danahers making multi-billion-dollar acquisitions in the space to have capacity for cell gene therapies, that’s a wake-up call.” Share

Dynamk Capital Investments

21 Investments

Dynamk Capital has made 21 investments. Their latest investment was in CellFE as part of their Series A on September 9, 2023.

CBI Logo

Dynamk Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/27/2023

Series A

CellFE

$22M

No

2

9/5/2023

Series A

Lucid Scientific

$7M

No

2

6/27/2023

Series B

Vernal Biosciences

$20M

No

2

5/25/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

4/27/2022

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/27/2023

9/5/2023

6/27/2023

5/25/2022

4/27/2022

Round

Series A

Series A

Series B

Series A

Seed VC

Company

CellFE

Lucid Scientific

Vernal Biosciences

Subscribe to see more

Subscribe to see more

Amount

$22M

$7M

$20M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

2

10

10

Dynamk Capital Portfolio Exits

2 Portfolio Exits

Dynamk Capital has 2 portfolio exits. Their latest portfolio exit was AbSci on July 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/22/2021

IPO

$99M

Public

6

10/14/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/22/2021

10/14/2019

Exit

IPO

Acquired

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

6

10

Dynamk Capital Fund History

2 Fund Histories

Dynamk Capital has 2 funds, including Dynamk Life Sciences Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/27/2021

Dynamk Life Sciences Fund

$32.25M

6

9/26/2017

Dynamk Capital Fund I

10

Closing Date

4/27/2021

9/26/2017

Fund

Dynamk Life Sciences Fund

Dynamk Capital Fund I

Fund Type

Status

Amount

$32.25M

Sources

6

10

Dynamk Capital Team

2 Team Members

Dynamk Capital has 2 team members, including current Founding Partner, Daniella Kranjac.

Name

Work History

Title

Status

Daniella Kranjac

Founding Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Daniella Kranjac

Subscribe to see more

Work History

Title

Founding Partner

Subscribe to see more

Status

Current

Subscribe to see more

Compare Dynamk Capital to Competitors

Aetion Logo
Aetion

Aetion operates as a healthcare analytics company. It provides decision-grade real-world evidence solutions to biopharma companies, payers, and regulatory agencies. It offers a platform that analyzes data from the real world to produce scientifically validated answers on treatments, effectiveness, and value. The company was founded in 2012 and is based in New York, New York.

D
DBL Partners

DBL Partners is a venture capital firm that invests in the cleantech, information technology, sustainable products and services, and healthcare sectors to deliver venture capital returns and enable social, environmental, and economic benefits. It was founded in 2002 and is based in San Francisco, California.

Harvard Bioscience Logo
Harvard Bioscience

Harvard Bioscience is a global developer and manufacturer in the life sciences sector, focusing on specialized products, primarily apparatus and scientific instruments. The company's main offerings include a broad range of equipment and instruments used to advance life science research, such as spectrophotometers, amino acid analyzers, and electrophysiology systems. Harvard Bioscience primarily sells to the pharmaceutical and biotechnology industries, as well as universities and government laboratories worldwide. It is based in Holliston, Massachusetts.

A
Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.

R
Regene Med

RegeneMed, Inc. is accelerating the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. RegeneMed possesses patented, proprietary, core technologies enabling the in vitro growth of engineered human tissues, including liver, GI tract, bone marrow and blood-brain barrier. These tissue-based in vitro model systems will accelerate drug development and aims to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry, per the company.

Sage Science Logo
Sage Science

Sage Science develops products for the life sciences research markets. Its mission is to provide new systems to streamline and improve sample preparation workflows for DNA and protein analysis.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.